Waystar: The Complete RCM Platform Review (2026)

30,000+ provider organizations. $835M in revenue. NASDAQ-listed. Here's what Waystar actually does well — and where it still falls short.

Overview

Waystar was formed in 2019 from the merger of Navicure and ZirMed — two clearinghouse-era players that had each expanded well beyond claim submission into broader RCM workflow tools. The combination created a cloud-native platform with scale across all provider types: health systems, physician groups, post-acute facilities, and dental.

The June 2024 NASDAQ IPO was a milestone — one of the few pure-play RCM technology companies to go public in recent years. It also brought capital for continued product investment, most visibly deployed in the 2023 acquisition of Iodine Software, which added AI-powered CDI capabilities to the portfolio.

Products & Platform

Waystar covers the full RCM workflow across five core areas:

• Claims Management — End-to-end submission, scrubbing, editing, real-time status tracking. Connects to 1,000+ payers. Rule-based pre-submission edits catch errors before they become denials.
• Eligibility & Benefits Verification — Real-time and batch eligibility across commercial, Medicare, and Medicaid. Integrates with most major PM/EHR systems to reduce front-desk manual lookup.
• Prior Authorization — Automated PA submission and status tracking via payer portal connections. Electronic PA where available. Still partially manual for complex clinical cases.
• Denial Management — Automated categorization, root cause analysis, appeal workflow routing. Identifies denial patterns across payers and CPT codes to inform upstream billing edits.
• Patient Payments — Digital billing, payment plans, financial assistance screening, and point-of-service collection. Increasingly important as patient responsibility grows as a share of total AR.
• CDI (via Iodine) — AI-powered clinical documentation analysis. Surfaces coding opportunities, generates physician queries, and improves case mix index and reimbursement accuracy.

AI Capabilities

Waystar markets AI aggressively — and unlike many vendors, they have substance behind the claims.

What's real: The CDI AI (Iodine-powered) is legitimate. It uses NLP to analyze clinical notes in real time, flagging documentation gaps and reducing the manual chart review burden for CDI specialists. This is one of the more mature AI applications in the RCM space with measurable CMI impact.

On denial management, ML-based denial classification and appeal likelihood scoring routes high-probability appeals to specialist queues and deprioritizes likely write-offs. Not perfect, but meaningfully better than manual triage at scale.

Who It's For

• Mid-to-large health systems that need a multi-module RCM platform with deep payer connectivity and enterprise analytics
• Physician groups and MSOs running 10+ providers who need standardized billing workflows across locations
• Post-acute and specialty providers — strong coverage in SNF, home health, and behavioral health billing
• Organizations evaluating CDI AI — the Iodine integration makes Waystar a strong option for facilities focused on documentation integrity and CMI improvement

It's less suited for small practices wanting simple billing software, or organizations needing deep payer contract intelligence (see PayorMap).

Pricing

Custom-quoted. No published pricing. Based on market information:

• Per-claim pricing roughly $0.05–$0.25, volume-tiered
• Module-based licensing for denial management, CDI, and analytics
• Enterprise agreements typically $200K–$1M+ annually for health systems
• All evaluations require a sales conversation — no self-serve trial

Integrations

Connects to Epic, Oracle Health (Cerner), MEDITECH, athenahealth, eClinicalWorks, NextGen, Greenway, and dozens of specialty-specific PM platforms. Payer connectivity breadth (1,000+) is one of the platform's core competitive advantages.

Pros & Cons

7 Powers Analysis

Bottom Line

Waystar is a credible, mature RCM platform with real AI substance behind the CDI and denial management capabilities. The Iodine acquisition gave Waystar a differentiated AI story that most clearinghouse-era competitors don't have. The IPO signals long-term investment capacity.

For health systems and large physician groups evaluating a multi-module RCM solution, Waystar belongs on the shortlist. For small practices or organizations laser-focused on payer contract intelligence, look elsewhere.